Skip to main content
. 2015 May 13;4(7):e1014232. doi: 10.1080/2162402X.2015.1014232

Figure 5.

Figure 5.

Anti-CD25 antibody treatment does not affect tumor growth. The percentage of tumor-infiltrating CD4+CD25+ T cells was quantified (n = 7 per group) based on flow cytometry analysis (A). Four doses of anti-CD25 (PC-61.5.3) or control antibody (HRPN) were injected intraperitoneally into WT (B) or IL-10−/− mice (C) at a dose of 400 μg/per mouse at 4-day intervals beginning on day 1 after J558 tumor cell challenge (n = 4 per group). Data shown are representative of 2 experiments with similar results.